<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860002</url>
  </required_header>
  <id_info>
    <org_study_id>VGHIRB-98-01-20A</org_study_id>
    <nct_id>NCT00860002</nct_id>
  </id_info>
  <brief_title>The Benefits and Limits of Laparoscopic Surgery for Uterine Fibroids</brief_title>
  <official_title>The Benefits and Limits of Laparoscopic Surgery for Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterine leiomyomas (i.e., fibroids, myomas) are the most common gynecologic tumors in women&#xD;
      of reproductive age (1). Clearly, the majority of such lesions are asymptomatic (2). Symptoms&#xD;
      directly attributable to these benign tumors represent the most common reason for laparotomy&#xD;
      in non-pregnant women in the United States (3,4), and also in Taiwan (5). Whereas in decades&#xD;
      past, hysterectomy was seen almost as a panacea for uterine leiomyomas, more recently&#xD;
      attention has been paid to the development of pharmaceutical agents and less-invasive&#xD;
      procedures (6). Frequently, such procedures are designed to retain the uterus (6). Of these,&#xD;
      myomectomy may be a choice among the uterine-sparing treatments for symptomatic uterine myoma&#xD;
      (7,8).&#xD;
&#xD;
      The surgical mode of access usually employed in myomectomy is traditional exploratory&#xD;
      laparotomy or its modification-mini-laparotomy (MLT) (9) or ultra-mini laparotomy (UMLT)&#xD;
      (10,11), though recently, laparoscopy (12-14) or a combination of laparoscopy and MLT (9),&#xD;
      vaginal surgery (15), and hysteroscopic myomectomy (16-21) have represented valid&#xD;
      alternatives. However, myomectomy alone provides varying degrees of symptom control and a&#xD;
      high percentage of recurrence, not only for the tumors themselves, but also for the symptoms.&#xD;
      For example, one study reported that symptom resolution varied from 84.0% to 100% depending&#xD;
      on different items and 21 (19.4%) of 108 patients experienced a recurrence after an average&#xD;
      interval of 16 months (range, 1.8-47.4 months) (22). Therefore, an alternative or additional&#xD;
      therapy might be required to provide longer durable symptom control and minimize tumor&#xD;
      recurrence. One of the strategies is laparoscopic uterine vessel occlusion (LUVO), also known&#xD;
      as laparoscopic uterine artery occlusion (LUAO) (23,24).&#xD;
&#xD;
      The rationale for using LUVO in the management of symptomatic myomas is found in the&#xD;
      successful experience with uterine-artery embolization (UAE), which was introduced in 1995 as&#xD;
      an alternative technique for treating fibroids (25). Since then it has become increasingly&#xD;
      accepted as a minimally invasive, uterine-sparing procedure, and studies have reported the&#xD;
      relief of excessive menstrual bleeding or pressure in 80-90% of patients (26-32). LUVO&#xD;
      provided similar relief of symptoms (89.4% with symptomatic improvement and 21.2% with&#xD;
      complete resolution of symptoms) in 2001 in a 7- to 12-month follow-up of 87 patients after&#xD;
      LUVO (33).&#xD;
&#xD;
      Since that time there has been rapid growth in the use of this treatment with various&#xD;
      modifications, such as simultaneous accompaniment with myomectomy either through laparoscopy&#xD;
      or ML, and there has been considerable research into its outcome (22,34-42). However, in our&#xD;
      previous data, we found that a combination of LUVO and myomectomy provided definite&#xD;
      effectiveness in symptom control for these women with symptomatic uterine myomas (98.1% to&#xD;
      100% symptom resolution depending on various kinds of items), minimized tumor recurrence, and&#xD;
      rendered the vast majority of re-interventions unnecessary (22). Myomectomy can be performed&#xD;
      by the laparoscopic approach or by ML when patients are undergoing the LUVO procedure. Before&#xD;
      2002, we often used ML to perform myomectomy (22). However, we have shortened the incision to&#xD;
      less than 4 cm, creating ultramini-laparotomy (UMLT) to perform myomectomy (10,11,43).&#xD;
&#xD;
      Since many conservative therapies might provide less or more therapeutic effects on the&#xD;
      symptom control and disease status, the aim of this prospective study tries to evaluate the&#xD;
      therapeutic outcomes of these symptomatic uterine myomas after different kinds of therapies&#xD;
      in the coming 5 years at Taipei Veterans General Hospital.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical technique, patient suffering, and outcomes (symptom control, relapse of symptoms, re-intervention, regularity of menstrual cycles and pregnancy outcome) in both groups.</measure>
    <time_frame>2-years and 5 years</time_frame>
  </primary_outcome>
  <number_of_groups>17</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Ultramini laparotomy (UMLT) myomectomy (UMLT-M) versus laparoscopic myomectomy (LM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Laparoscopically aided myomectomy (LAM) versus LM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>LAM versus UMLT-M</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Mini laparotomy myomectomy (ML-M) versus UMLT-M</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <description>Laparoscopic uterine artery occlusion with blockage of anastomosis between the uterine and ovarian vessels (LUVO) versus laparoscopic uterine artery occlusion without blockage of anastomosis between the uterine and ovarian vessels (LUAO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <description>LUVO+LAM versus LUAO+LAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <description>LUVO+LM versus LUAO+LM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <description>LUVO+UMLT-M versus LUAO+UMLT-M</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <description>LUVO versus UMLT-UVO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10</arm_group_label>
    <description>UMLT-UVO versus UMLT-UAO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11</arm_group_label>
    <description>LUAO versus UMLT-UAO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12</arm_group_label>
    <description>UMLT-UVO+UMLT-M versus UMLT-UAO+UMLT-M</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13</arm_group_label>
    <description>LUVO versus LM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14</arm_group_label>
    <description>LUVO versus LAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15</arm_group_label>
    <description>LUVO versus LUAO+LM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16</arm_group_label>
    <description>LUVO versus LUAO+UMLT-M</description>
  </arm_group>
  <arm_group>
    <arm_group_label>17</arm_group_label>
    <description>LUVO versus LUAO+LAM</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women between 2009 and 2014 booked for treatment who had symptomatic uterine myomas, will&#xD;
        be included in the present study. All the treatments for symptomatic uterine myomas,&#xD;
        including medical treatment with different kinds of medication, and uterine-sparing surgery&#xD;
        including myomectomy, which is performed through traditional exploratory laparotomy (LT),&#xD;
        mini-laparotomy (MLT), ultramini-laparotomy (UMLT), laparoscopy (L), the vagina (V) or&#xD;
        hysteroscopy (H), and LUVO and combination therapy, and the definite treatment of&#xD;
        hysterectomy, through different routes, such as vagina, laparoscopic assistance, and&#xD;
        convention exploratory laparotomy. All patients should have uterine fibroids with symptoms,&#xD;
        comprising either menstrual problems such as menorrhagia and pain, or compression syndrome,&#xD;
        including a bulge-like sensation and frequency. These women will be informed that they can&#xD;
        choose to be treated with any one of the above-mentioned procedures, based on their&#xD;
        willingness and preference.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  symptomatic;&#xD;
&#xD;
          -  having a wish to retain their uterus;&#xD;
&#xD;
          -  an absence of previous abdominal or pelvic surgery;&#xD;
&#xD;
          -  a number of visible uterine masses (myomas) less than or equal to 5 intramural or&#xD;
             sub-serous myomas (without peduncle);&#xD;
&#xD;
          -  a maximum diameter of no more than 8 cm;&#xD;
&#xD;
          -  an absence of prominent or significant pelvic adhesion on clinical evaluation; AND&#xD;
&#xD;
          -  at least a 2-year thorough follow-up record available.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  without pathological diagnosis of myoma if the specimen can be obtained; OR&#xD;
&#xD;
          -  any violation the above-mentioned criteria.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wen-Hsun Chang, NB</last_name>
    <phone>886921125253</phone>
    <email>whchang@vghtpe.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling-Wei Yang, MS</last_name>
    <phone>886928994443</phone>
    <email>sammy680106@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peng-Hui Wang</name>
      <address>
        <city>201, Section 2, Shih-Pai Road, Taipei</city>
        <state>Taipei</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Hsun Chang, NB</last_name>
      <phone>886921125253</phone>
      <email>whchang@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Peng-Hui Wang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>June 6, 2010</last_update_submitted>
  <last_update_submitted_qc>June 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Peng-Hui Wang, M.D., Ph.D., Associate Professor</name_title>
    <organization>Department of Obstetrics and Gynecology, Taipei Veterans General Hospital</organization>
  </responsible_party>
  <keyword>myomectomy</keyword>
  <keyword>uterine artery occlusion</keyword>
  <keyword>uterine vessel occlusion</keyword>
  <keyword>fibroids</keyword>
  <keyword>leiomyomas</keyword>
  <keyword>Surgical technique, patient suffering and outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

